Bellus Health announces results from camlipixant bioavailability study

BELLUS Health announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release formulation of camlipixant in comparison to a twice-daily Immediate Release formulation. Camlipixant is the Company’s twice-daily, oral P2X3 antagonist product candidate for the treatment of RCC currently being investigated in the CALM Phase 3 program. "We are pleased with the outcome of the bioavailability equivalence study, which establishes the proof of concept for developing a once-daily formulation of camlipixant, our potentially best-in-class P2X3 inhibitor in Phase 3 development," commented Roberto Bellini, President and Chief Executive Officer of BELLUS Health. "At BELLUS Health, we are working to better the lives of individuals suffering from persistent cough, and these results reflect our continued progress to establish and differentiate camlipixant as the market leading option for RCC patients. We look forward to providing additional data from this study at an upcoming medical conference." This Phase 1, open-label bioavailability equivalence study was designed to assess the safety, tolerability, and pharmacokinetic profile of a single dose, once-daily ER formulation of camlipixant versus a twice-daily IR reference formulation in 16 healthy adult subjects.